Form 4: Heartflow CEO Granted Significant Equity Awards

Heartflow, Inc. CEO John C.M. Farquhar received grants of 59,868 restricted stock units and options for 314,603 shares of common stock.

Summary

• John C.M. Farquhar, CEO and Director of Heartflow, Inc., was granted 59,868 restricted stock units (RSUs) on August 7, 2025.
• These RSUs will vest in 1/16th increments on each quarterly anniversary of the August 7, 2025 vesting commencement date, contingent on his continued service.
• Additionally, Mr. Farquhar was granted stock options for 314,603 shares of common stock with an exercise price of $19 per share, also on August 7, 2025.
• These stock options have an expiration date of August 7, 2035, and will vest in 1/48th increments on each monthly anniversary of the August 7, 2025 vesting commencement date, subject to his continued service.
• Following these transactions, Mr. Farquhar directly beneficially owns 433,248 shares of common stock and 314,603 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing indicates standard executive compensation, which is generally positive for aligning management incentives with shareholder interests, though it introduces potential future dilution. It's a neutral-to-positive event for company stability and leadership retention.

Positives

• The grants incentivize the CEO, John C.M. Farquhar, to remain with Heartflow, Inc. and contribute to its long-term success.
• Equity awards align the CEO's interests with those of shareholders, as the value of the awards is tied to the company's stock performance.
• The vesting schedules promote long-term retention and performance.

Negatives

• The issuance of new equity awards could lead to potential future dilution for existing shareholders as RSUs vest and options are exercised.

Future Outlook

The vesting schedules for both the restricted stock units and stock options extend into the future, indicating a long-term incentive structure tied to the CEO's continued service and the company's performance. The RSUs vest quarterly over four years, and the options vest monthly over four years.

Industry Context

This filing represents a standard practice in executive compensation within the technology and healthcare sectors, where equity grants are commonly used to attract, retain, and incentivize key leadership by aligning their financial interests with long-term shareholder value creation.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options as a significant component of executive compensation is a common practice across the technology and healthcare industries, similar to compensation structures seen at companies like Medtronic, Intuitive Surgical, or other medical device/software firms.
• Vesting schedules tied to continued service over several years (e.g., 4 years for both RSUs and options) are typical for executive equity awards, aiming to ensure long-term commitment and performance, comparable to practices at companies such as Apple or Google for their senior executives.
• An exercise price equal to the market price on the grant date (implied by $0 price for the derivative and $19 exercise price) is standard for incentive stock options or non-qualified stock options.

Related Party Transactions

• The equity grants to the CEO are considered related party transactions, as they involve compensation to an executive officer.

Stakeholder Impact

• Shareholders: Potential future dilution from the vesting and exercise of RSUs and stock options, but also benefit from incentivized leadership focused on long-term value creation.
• Employees: May signal stability in leadership and a commitment to executive retention.
• Management: Directly benefits from significant equity awards, aligning their personal wealth with company performance.

Next Steps

• The restricted stock units will begin vesting on August 7, 2025, with 1/16th vesting quarterly thereafter.
• The stock options will begin vesting on August 7, 2025, with 1/48th vesting monthly thereafter.

Key Dates

Recommendation

This Form 4 filing reports routine executive compensation and does not contain information that would fundamentally alter the investment thesis for Heartflow, Inc. While the grants incentivize the CEO, they are a standard part of compensation and do not indicate a significant positive or negative shift in the company's operational or financial outlook. Therefore, a "hold" recommendation is appropriate, pending further operational or financial news.

Keywords

Heartflow, HTFL, John C.M. Farquhar, CEO, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Executive Compensation, Insider Transaction